Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
283
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Shanghai Henlius Biotech
•
22 Jan 2025 13:27
Henlius (2696 HK): Deal Break as HKEx Merger Arb Rulebooks Are Rewritten
The 27.5% share price decline since 9 January points to a well-flagged deal break. Nevertheless, precedent deal-breaks suggest that the shares...
Arun George
Follow
727 Views
Share
bearish
•
Shanghai Henlius Biotech
•
19 Jan 2025 08:03
Weekly Deals Digest (19 Jan) - Henlius, GA Pack, Lifestyle China, Jamco, Macromill, Insignia, AVJ
Last week, notable developments occurred in Event-Driven (Canvest, Henlius, GA Pack, Lifestyle China, Haitong/GJTA, Jamco, Macromill, 7&i,...
Arun George
Follow
424 Views
Share
bullish
•
Shanghai Henlius Biotech
•
18 Jan 2025 22:30
Last Week In Event SPACE: Shanghai Henlius, Malaysia Airports, Kokusai Electric, Smart Share
It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...
David Blennerhassett
Follow
477 Views
Share
bearish
•
Shanghai Henlius Biotech
•
15 Jan 2025 16:42
Henlius (2696 HK): Musings on the Deal Break Price
In the absence of a last-ditch effort by Fosun Pharma to rescue the deal, the key question is the potential deal break price. I use four methods to...
Arun George
Follow
655 Views
Share
bearish
•
Shanghai Henlius Biotech
•
14 Jan 2025 15:22
Henlius (2696 HK): Hurtling Towards a Likely Deal Break
LVC’s trading behaviour suggests that it is likely to block the vote. Fosun Pharma has two potential options to secure LVC’s backing. Both have...
Arun George
Follow
562 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.6
x